Vol. 45 (6): 1090-1093, November – December, 2019
Fernando Korkes 1, Juan Palou 2
1 Disciplina de Urologia, Faculdade de Medicina do ABC, Santo André, SP, Brasil; 2 Fundacion Puigvert Universitat Autonoma de Barcelona, Espanha
Bladder cancer is a common disease, and for T2-T4 stages, radical cystectomy is the first treatment option (1). An interesting Swedish study has evaluated the natural history of urothelial bladder cancer. After 6 months of diagnosis, 38% of patients develop metastasis if untreated (2). Five-year Cancer-specific survival is as low as 14% in such scenery, and overall survival is only 5% (2).